SCHEMBL372136

SCHEMBL372136

CSC(SC)=C1C(=O)OC(C)(C)OC1=O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.50
ACP1 P24666 2/20 0.42
CDC25B P30305 2/20 0.42
ALDH1A1 P00352 10/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 2/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HSD17B10 Q99714 1/20 0.32
HTT P42858 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13437616 0.78 PTPN1 (0.47) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL10995517 0.78 PTPN1 (0.46) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL10995738 0.77 PTPN1 (0.49) PTPN1ACP1CDC25B
SCHEMBL1670284 0.77 PTPN1 (0.46) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL10996134 0.75 HSD11B1 (0.36) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL70825 0.73 PTPN1 (0.56) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL13403500 0.71 PTPN1 (0.59) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL8194669 0.71 PTPN1 (0.59) PTPN1ACP1CDC25BALDH1A1L3MBTL1
SCHEMBL9730908 0.71
SCHEMBL5146314 0.70 PTPN1 (0.57) PTPN1ACP1CDC25BALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2025-11-18 US claimed
CN-115997016-A Composition comprising nucleic acid nanoparticles having modular functional groups 西克斯福德生物科学有限公司 2023-04-21 CN claimed
EP-4143316-A2 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2023-03-08 EP claimed
US-20220370635-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY SIXFOLD BIOSCIENCE LTD (GB) 2022-11-24 US claimed
US-11357865-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2022-06-14 US claimed
WO-2021220053-A2 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2021-11-04 WO claimed
US-20210330810-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2021-10-28 US claimed
US-4547516-A Antisecretory agents derived from meldrum's acid AMERICAN HOME PRODUCTS CORPORATION (US) 1985-10-15 US claimed
US-20260049991-A1 SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS GLYPHIC BIOTECHNOLOGIES INC (US) 2026-02-19 US disclosed
EP-4655289-A1 SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS Glyphic Biotechnologies, Inc. (US) 2025-12-03 EP disclosed
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2025-11-18 US disclosed
US-20250289830-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2025-09-18 US disclosed
EP-4594520-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2025-08-06 EP disclosed
US-12351591-B2 KRas inhibitors ELI LILLY AND COMPANY (US) 2025-07-08 US disclosed
US-5179216-A Anticholesterol agents and atherosclerosis AMERICAN HOME PRODUCTS CORPORATION (US) 1993-01-12 US disclosed
US-5177219-A N-phenyl-N'-thienylmethyl-bis-diamino-5-methylene-1,3-dioxane-4,6-dione compounds AMERICAN HOME PRODUCTS CORPORATION (US) 1993-01-05 US disclosed
US-5164505-A Anticholesterol, inhibitors of acyl-coenzyme A:cholesterol-acyl transferase (ACAT) AMERICAN HOME PRODUCTS CORPORATION (US) 1992-11-17 US disclosed
US-5136039-A N,N',N'-trisubstituted-5-bis-aminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase AMERICAN HOME PRODUCTS CORPORATION (US) 1992-08-04 US disclosed
EP-0471493-A1 N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase AMERICAN HOME PRODUCTS CORPORATION (US) 1992-02-19 EP disclosed
US-4547516-A Antisecretory agents derived from meldrum's acid AMERICAN HOME PRODUCTS CORPORATION (US) 1985-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357865-B2 Compositions containing nucleic acid nanoparticles with modular functionality NCL, NSUN3, POLN PTPN1 2682/4885ACP1 361/4885CDC25B 3875/4885
US-20260049991-A1 SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS CHAMP1, S100A11, TFIP11 PTPN1 2383/4885ACP1 16/4885CDC25B 3887/4885
US-20220370635-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY NCL, NSUN3, POLN PTPN1 2682/4885ACP1 361/4885CDC25B 3875/4885
US-20210330810-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY NCL, NSUN3, POLN PTPN1 2682/4885ACP1 361/4885CDC25B 3875/4885
US-12351591-B2 KRas inhibitors KRAS, NRAS, HRAS PTPN1 547/4885ACP1 3885/4885CDC25B 291/4885
US-12472267-B2 Compositions containing nucleic acid nanoparticles with modular functionality NCL, NSUN3, POLN PTPN1 2682/4885ACP1 361/4885CDC25B 3875/4885
US-20250289830-A1 KRAS INHIBITORS KRAS, NRAS, HRAS PTPN1 547/4885ACP1 3885/4885CDC25B 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.